Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Abstract Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8 + cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pathway can be targeted remains to be determined. Here, we report that methylene blue (MB), an FDA‐approved chemical for treating methemoglobinemia, potently inhibits PD‐1 signaling. MB enhances the cytotoxicity, activation, cell proliferation, and cytokine‐secreting activity of CTL inhibited by PD‐1. Mechanistically, MB blocks interaction between Y248‐phosphorylated immunoreceptor tyrosine‐based switch motif (ITSM) of human PD‐1 and SHP2. MB enables activated CTL to shrink PD‐L1 expressing tumor allografts and autochthonous lung cancers in a transgenic mouse model. MB also effectively counteracts the PD‐1 signaling on human T cells isolated from peripheral blood of healthy donors. Thus, we identify an FDA‐approved chemical capable of potently inhibiting the function of PD‐1. Equally important, our work sheds light on a novel strategy to develop inhibitors targeting PD‐1 signaling axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even though SHP2 is important for inhibitory signaling of PD‐1 in most cases, T lymphocyte SHP2 deficiency can still be detrimental by reacting to the treatment of anti‐PD‐1 antibodies in vitro, thus revealing an alternate signaling pathway [284, 285].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [284]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, interfering with the interaction of SHP2 with programmed death-1 (PD-1) is a potent alternative to immuno-oncologic approaches aiming to block PD-1 with antibodies in several cancers [53].”
From The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling (2021) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundSelf-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961 · cited 2×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundSelf-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“In contrast, PD-1-deficient mice of C57BL/6 background develop and grow apparently normally, with autoimmune disease observed in late stage of their life (Nishimura et al, 1998, 1999).”
BackgroundMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381 · cited 1×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 1×
“Unfortunately, PD-1 inhibitors currently used in clinic show severe, sometimes fatal, side effects (Johnson et al, 2016; Moslehi et al, 2018).”
BackgroundT cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Self-citationDecker, T., & Lohmann-Matthes, M.-L. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90310-9 · Cited by 1,359 · cited 1×
“Measuring lactate dehydrogenase (LDH) released by target tumor cells into medium is another accurate assay to determine CTL cytotoxicity (Decker & Lohmann-Matthes, 1988).”
MethodYokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 17×
“Although SHP1 and SHP2 were earlier reported to be recruited by PD-1 to exert immunoinhibitory function, it is been confirmed that SHP2 is the main effecter (Yokosuka et al, 2012).”
BackgroundInfluentialIntroduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092 · cited 9×
“Earlier reports showed that PD-L1 stimulation led to phosphorylation of Y248 in ITSM motif of PD-1, essential for recruitment of SHP2 to inhibit TCR signaling (Yokosuka et al, 2012).”
BackgroundInfluentialBlockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Self-citationRescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · cited 2×
“CD28 phosphorylation in CTLs is a critical determinant of treatment effect of PD-1 inhibitors (Hui et al, 2017; Kamphorst et al, 2017).”
BackgroundIncreased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942 · cited 1×
“Unfortunately, PD-1 inhibitors currently used in clinic show severe, sometimes fatal, side effects (Johnson et al, 2016; Moslehi et al, 2018).”
BackgroundAllosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · cited 1×
“…by PD-1, we consistently found that MB did not significantly enhance luciferase activity in JPluc when SHP2 was knockout through CRISPR/CAS9 system (designated JP-luc-sgSHP2) or in the presence of SHP099, an SHP2-specific inhibitor of phosphatase (Chen et al, 2016) (Fig EV3C, Appendix Fig S3O).”
BackgroundSelf-citationPatnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807 · cited 1×
“…nM of MB elicited stronger proliferation of CD8+ T cells than 25 lg/ml of pembrolizumab or 20 lg/ml nivolumab, respectively (serum concentration achievable in patients for pembrolizumab (Patnaik et al, 2015) and nivolumab (Brahmer et al, 2010), respectively) (Figs 5A and EV5A, Appendix Fig S5A).”
BackgroundPD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · cited 3×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine e11571 | 2020 1 of 17 Signaling pathways leading from binding of PD-L1/2 to PD-1 down to inhibition of T-cell activation and cytokine expression have been relatively clear (Riley, 2009; Xia et al, 2016).”
BackgroundInfluentialNishimura, H. (1998) · International Immunology · doi:10.1093/intimm/10.10.1563 · Cited by 500
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462 · cited 1×
“We generated TetO-EGFR L858R/CC10rtTA bitransgenic mice (designated EC mice) following our earlier protocol (Ji et al, 2006).”
MethodSelf-citationStructural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8730 · Cited by 422 · cited 1×
“Earlier, targeting interaction between PD-1 and PD-L1 has been tried (Zak et al, 2016), including CA-170 (Bojadzic & Buchwald, 2018), BMS-1001 and BMS-1166 (Skalniak et al, 2017), and peptides (Chang et al, 2015; Li et al, 2018).”
BackgroundFcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409 · cited 1×
“Lines of evidence suggest that the fragment crystallizable regions (Fc region) of these antibodies play a role in mediating treatment effect (Dahan et al, 2015).”
BackgroundBlocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy
Chang, H., Liu, B., Qi, Y., Zhou, Y., Chen, Y., Pan, K., Li, W., Zhou, X., Ma, W., Fu, C., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506225 · Cited by 397 · cited 1×
“Earlier, targeting interaction between PD-1 and PD-L1 has been tried (Zak et al, 2016), including CA-170 (Bojadzic & Buchwald, 2018), BMS-1001 and BMS-1166 (Skalniak et al, 2017), and peptides (Chang et al, 2015; Li et al, 2018).”
BackgroundSelf-citationA versatile system for rapid multiplex genome-edited CAR T cell generation
Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 397 · cited 1×
“The gRNA targeting sequences used in this study were as follows: Human PD-1-gRNA: GGCCAGGATGGTTCTTAGGT (Ren et al, 2017); Human SHP2-gRNA: CTGGACCAACTCAGCCAAAG; Mouse SHP2-gRNA: GAGGAACATGACATCGCGG (Ruess et al, 2018).”
MethodMutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370 · cited 1×
“The gRNA targeting sequences used in this study were as follows: Human PD-1-gRNA: GGCCAGGATGGTTCTTAGGT (Ren et al, 2017); Human SHP2-gRNA: CTGGACCAACTCAGCCAAAG; Mouse SHP2-gRNA: GAGGAACATGACATCGCGG (Ruess et al, 2018).”
MethodMolecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
Agazie, Y. M., & Hayman, M. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7875-7886.2003 · Cited by 306 · cited 16×
“We expressed SHP2-Nluc and EGFR-C-luc or FGFR1-C-luc in 293T cells, such that luciferase activity is a readout for interaction between SHP2 and corresponding RTKs and checked the impact of MB on interaction between SHP2 and RTKs through monitoring luciferase activity.”
BackgroundInfluentialSkalniak, L., Zak, K. M., Guzik, K., Magiera, K., Musielak, B., Pachota, M., Szelazek, B., Kocik, J., Grudnik, P., Tomala, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20050 · Cited by 294 · cited 1×
“Earlier, targeting interaction between PD-1 and PD-L1 has been tried (Zak et al, 2016), including CA-170 (Bojadzic & Buchwald, 2018), BMS-1001 and BMS-1166 (Skalniak et al, 2017), and peptides (Chang et al, 2015; Li et al, 2018).”
BackgroundRan, X., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 263 · cited 1×
“Currently, PPIs are targeted by an increasingly larger number of small molecular chemicals (Ran & Gestwicki, 2018).”
BackgroundMolecular mechanism of SHP2 activation by PD-1 stimulation
Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., Brandt, H. J., Kirkpatrick, J., Rios, P., Schamel, W. W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4458 · Cited by 262 · cited 1×
“PD-1 predominantly recruits SHP-2 (Yokosuka et al, 2012), with details for signaling worked out very recently (Marasco et al, 2020).”
BackgroundInterleukin 2 and its receptors: recent advances and new immunological functions
Thèze, J., Alzari, P. M., & Bertoglio, J. (1996) · Immunology Today · doi:10.1016/0167-5699(96)10057-c · Cited by 231 · cited 4×
“FACS analysis revealed that 100 nM of MB potently recovered CD25 expression in CTLs suppressed by PD-L1 in this system (Fig 2C and D, Appendix Fig S2B).”
BackgroundInfluentialBritish National Formulary (BNF) 50
Mehta, D. K. (2005) · Cited by 205
Requirement for Transcription Factor NFAT in Interleukin-2 Expression
Chow, C.-W., Rincón, M., & Davis, R. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2300 · Cited by 198 · cited 1×
“…enhances cytotoxicity of activated CTL against PD-L1 expressing target cells We took advantage of engineered T-cell systems in which luciferase gene was placed under control of NFAT binding sequence, such that luciferase activity could serve as surrogate IL-2 mRNA transcription (Chow et al, 1999).”
BackgroundTargeting Protein-Protein Interaction by Small Molecules
Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195 · cited 1×
“Recent mutational study, however, revealed “hot spots” anchor residues that contributed the most to the binding free energy of the protein–protein complex (Jin et al, 2014).”
BackgroundPeptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
Li, C., Zhang, N., Zhou, J., Ding, C., Jin, Y., Cui, X., Pu, K., & Zhu, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0035 · Cited by 161
Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo
Rota, G., Niogret, C., Dang, A. T., Barros, C. R., Fonta, N. P., Alfei, F., Morgado, L., Zehn, D., Birchmeier, W., Vivier, E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.026 · Cited by 155 · cited 1×
“Recently, Rota et.al. reported that SHP2 was apparently dispensable PD-1 signaling in vivo (Rota et al, 2018).”
BackgroundCelis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.041 · Cited by 154 · cited 1×
“In the case of SHP2 knockout, PD-1 recruits SHP-1 and remains functional (Celis-Gutierrez et al, 2019).”
BackgroundT cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm, W., Thoma, S. J., Leithäuser, F., Mӧller, P., Schirmbeck, R., & Reimann, J. (1998) · PubMed · Cited by 150
Fluorescence complementation: an emerging tool for biological research
Shyu, Y. J., & Hu, C. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.07.006 · Cited by 147 · cited 1×
“Source data are available online for this figure. ª 2020 The Authors EMBO Molecular Medicine e11571 | 2020 7 of 17 complementation assay (Shyu & Hu, 2008) by fusing PD-1 and SHP2 to C- and N-terminal half of firefly luciferase respectively (designated PD-1-C-luc and SHP2-N-luc, respectively).”
BackgroundPD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dolan, D. E., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100308 · Cited by 145 · cited 1×
“Some of these antibodies have been approved for clinical trial or usage (Dolan & Gupta, 2014).”
BackgroundBaddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., & Wischik, C. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219352 · Cited by 143
T Cell-Mediated, IFN-γ-Facilitated Rejection of Murine B16 Melanomas
Böhm, W., Thoma, S., Leithäuser, F., Möller, P., Schirmbeck, R., & Reimann, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.897 · Cited by 122
Venetoclax: A new wave in hematooncology
Mihályová, J., Jelínek, T., Growková, K., Hrdinka, M., Šimíček, M., & Hájek, R. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.02.002 · Cited by 110 · cited 1×
“Impressive successes have been reported with inhibitors of protein–protein interactions (iPPIs) in clinic as exemplified by Bcl-2 inhibitor, Venclexta (ABT-199) (Mihalyova et al, 2018).”
BackgroundTumor necrosis factor‐α production induced in T lymphocytes through the AIM/CD69 activation pathway
Santis, A. G., Campanero, M. R., Alonso, J. L., Tugores, A., Alonso, M. A., Yagüe, E., Pivel, J. P., & Sánchez‐Madrid, F. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220521 · Cited by 91 · cited 3×
“Similar effect was seen on CD69 expression (Fig 2C and D).”
BackgroundBojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 82 · cited 1×
“Earlier, targeting interaction between PD-1 and PD-L1 has been tried (Zak et al, 2016), including CA-170 (Bojadzic & Buchwald, 2018), BMS-1001 and BMS-1166 (Skalniak et al, 2017), and peptides (Chang et al, 2015; Li et al, 2018).”
BackgroundTian, R., Wang, H., Gish, G. D., Petsalaki, E., Pasculescu, A., Shi, Y., Mollenauer, M., Bagshaw, R. D., Yosef, N., Hunter, T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503286112 · Cited by 76 · cited 5×
“We further showed that MB treatment enhanced recruitment of P85 by CD28 (Fig 3H), consistent with earlier report that activated CD28 recruited P85 (Tian et al, 2015).”
ResultInfluentialSignaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.09.002 · Cited by 75 · cited 2×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine e11571 | 2020 1 of 17 Signaling pathways leading from binding of PD-L1/2 to PD-1 down to inhibition of T-cell activation and cytokine expression have been relatively clear (Riley, 2009; Xia et al, 2016).”
BackgroundInfluentialAnalysis of Protein Phosphorylation Using Phos‐Tag Gels
Nagy, Z., Comer, S. P., & Smolenski, A. (2018) · Current Protocols in Protein Science · doi:10.1002/cpps.64 · Cited by 59 · cited 1×
“Phos-tag SDS–PAGE is useful for separating a phosphorylated protein from its unphosphorylated counterpart by slower moving rate (Nagy et al, 2018).”
BackgroundAnalysis of protein phosphorylation using Phos-tag gels
O’Donoghue, L., & Smolenski, A. (2022) · Journal of Proteomics · doi:10.1016/j.jprot.2022.104558 · Cited by 57
Hejtmancik, M. R. (2002) · Toxicological Sciences · doi:10.1093/toxsci/65.1.126 · Cited by 47
Frs2α and Shp2 signal independently of Gab to mediate FGF signaling in lens development
Li, H., Tao, C., Cai, Z., Hertzler-Schaefer, K., Collins, T. N., Wang, F., Feng, G.-S., Gotoh, N., & Zhang, X. (2013) · Journal of Cell Science · doi:10.1242/jcs.134478 · Cited by 37 · cited 7×
“We expressed SHP2-Nluc and EGFR-C-luc or FGFR1-C-luc in 293T cells, such that luciferase activity is a readout for interaction between SHP2 and corresponding RTKs and checked the impact of MB on interaction between SHP2 and RTKs through monitoring luciferase activity.”
BackgroundInfluentialNivolumab in non-small-cell lung cancer with EGFR mutation
Yoshida, H., Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Tsuji, T., Nomizo, T., Yasuda, Y., Funazo, T. Y., & Hirai, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx745 · Cited by 35 · cited 1×
“Clinical data have shown that PD-1 antibodies are not effective in treating EGFR mutation-positive lung cancer patients (Yoshida et al, 2018).”
Background
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 204
“The core of PD-1’s inhibitory function lies in the ITSM-Y248 residue rather than the ITIM-Y223 residue 12 .”
BackgroundPan, J., Zhou, L., Zhang, C., Xu, Q., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01038-3 · Cited by 129
“found that methylene blue prevented SHP2 from binding with Y248-phosphorylated PD-1 and therefore enhanced the tumorkilling effect of CTLs.(264) In addition, inducing the degradation and ubiquitination of SHP2 through its intracellular E3 ligase, FBXW7, was an outstanding approach that interrupted the downstream signa…”
BackgroundA comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Metadata
- Authors
- Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., Xu, C., Zhang, Z., Gao, S., Zhou, P., Ding, K., & Chen, L.
- Affiliations
- Jinan University (CN)
- Sun Yat-sen University Cancer Center (CN)
- University of East Anglia (GB)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Zhou, Penghui
- Ding, Ke
- Chen, Liang
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-05-11
- Volume
- 12
- Issue
- 6
- Pages
- e11571-e11571
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7278553
- OpenAlex
- W3023016632
- Cited by
- 62
- References
- 51
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 16 · 2023: 7 · 2022: 17 · 2021: 6 · 2020: 3
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81672309, 81972778, 31800723, 31701174)
- Guangzhou Research Project of Science and Technology for Citizen Health (201803010124)
- Science and Technology Program of Guangdong (2017B020227001)
- Fundamental Research Funds for the Central Universities (21618326)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-1, SHP2, methylene blue, PD-1/PD-L1 axis, CD8+ cytotoxic T lymphocytes, lung cancer, immunotherapy, tumor allografts
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Antineoplastic Agents, Humans, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.